SmithKline Beecham U.K. consolidation
Firm will move its pharmaceutical production from its Welwyn Garden City, Hertfordshire facility to its plant in Crawley, Sussex over an 18-24 month period. However, Welwyn Garden City will serve as the new headquarters of SmithKline Beecham Pharmaceuticals' U.K. operation, beginning in March. Also, the company says it plans to consolidate all pharmaceutical distribution activities at its Ridgeway site in Welwyn Garden City. The move is expected to be completed by mid-1990. A total of 344 positions will be eliminated over two years.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.